1. 54. tGLI1 IS AN ACTIONABLE THERAPEUTIC TARGET IN BREAST CANCER BRAIN METASTASES. (4th August 2020) Authors: Doheny, Daniel; Sirkisoon, Sherona; Rimkus, Tadas; Zhu, Dongqin; Aguayo, Noah; Anguelov, Marlyn; Manore, Sara; Regua, Angelina; Thomas, Alexandra; Henson-Masters, Adrianna; Strowd, Roy; Lo, Hui-Wen Journal: Neuro-oncology advances Issue: Volume 2(2020)Supplement 2 Page Start: ii11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Breast cancer extracellular vesicles-derived miR-1290 activates astrocytes in the brain metastatic microenvironment via the FOXA2→CNTF axis to promote progression of brain metastases. (1st August 2022) Authors: Sirkisoon, Sherona R.; Wong, Grace L.; Aguayo, Noah R.; Doheny, Daniel L.; Zhu, Dongqin; Regua, Angelina T.; Arrigo, Austin; Manore, Sara G.; Wagner, Calvin; Thomas, Alexandra; Singh, Ravi; Xing, Fei; Jin, Guangxu; Watabe, Kounosuke; Lo, Hui-Wen Journal: Cancer letters Issue: Volume 540(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. BSCI-02. tGLI1 IS A NOVEL, ACTIONABLE TARGET FOR THE TREATMENT OF BREAST CANCER BRAIN METASTASES. (12th August 2019) Authors: Doheny, Daniel; Sirkisoon, Sherona; Rimkus, Tadas; Zhu, Dongqin; Aguayo, Noah; Harrison, Alexandria; Anguelov, Marlyn; Xing, Fei; Metheny-Barlow, Linda; Watabe, Kounosuke; Thomas, Alexandra; Masters, Adrianna Henson; Strowd, Roy; Lo, Hui-Wen Journal: Neuro-oncology advances Issue: Volume 1(2019)Supplement 1 Page Start: i1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. BSCI-13. TUMOR-SPECIFIC tGLI1 TRANSCRIPTION FACTOR MEDIATES BREAST CANCER BRAIN METASTASIS VIA ACTIVATING METASTASIS-INITIATING CANCER STEM CELLS AND ASTROCYTES IN THE TUMOR MICROENVIRONMENT. (12th August 2019) Authors: Sirkisoon, Sherona; Carpenter, Richard; Rimkus, Tadas; Doheny, Daniel; Zhu, Dongqin; Aguayo, Noah; Anguelov, Marlyn; Arrigo, Austin; Regua, Angelina; Xing, Fei; Chan, Michael; Metheny-Barlow, Linda; Watabe, Kounosuke; Lo, Hui-Wen Journal: Neuro-oncology advances Issue: Volume 1(2019)Supplement 1 Page Start: i3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. BSCI-14. tGLI1 is an actionable therapeutic target in breast cancer brain metastases. (9th August 2021) Authors: Doheny, Daniel; Manore, Sara; Wong, Grace; Zhu, Dongqin; Sirkisoon, Sherona; Rimkus, Tadas; Anguelov, Marlyn; Aguayo, Noah; Regua, Angelina; Cox, Anderson O'Brian; Furdui, Cristina; Thomas, Alexandra; Masters, Adrianna Henson; Strowd, Roy; Lo, Hui-Wen Journal: Neuro-oncology advances Issue: Volume 3(2021)Supplement 3 Page Start: iii4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. Issue 2 (10th November 2020) Authors: Chen, Xiaofeng; Wu, Xiaofeng; Wu, Hao; Gu, Yanhong; Shao, Yang; Shao, Qianwen; Zhu, Feipeng; Li, Xiao; Qian, Xiaofeng; Hu, Jun; Zhao, Fengjiao; Mao, Weidong; Sun, Jing; Wang, Jian; Han, Gaohua; Li, Changxian; Xia, Yongxiang; Seesaha, Poshita Kumari; Zhu, Dongqin; Li, Huajun Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. Issue 2 (10th November 2020) Authors: Chen, Xiaofeng; Wu, Xiaofeng; Wu, Hao; Gu, Yanhong; Shao, Yang; Shao, Qianwen; Zhu, Feipeng; Li, Xiao; Qian, Xiaofeng; Hu, Jun; Zhao, Fengjiao; Mao, Weidong; Sun, Jing; Wang, Jian; Han, Gaohua; Li, Changxian; Xia, Yongxiang; Seesaha, Poshita Kumari; Zhu, Dongqin; Li, Huajun Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. Issue 2 (10th November 2020) Authors: Chen, Xiaofeng; Wu, Xiaofeng; Wu, Hao; Gu, Yanhong; Shao, Yang; Shao, Qianwen; Zhu, Feipeng; Li, Xiao; Qian, Xiaofeng; Hu, Jun; Zhao, Fengjiao; Mao, Weidong; Sun, Jing; Wang, Jian; Han, Gaohua; Li, Changxian; Xia, Yongxiang; Seesaha, Poshita Kumari; Zhu, Dongqin; Li, Huajun Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. Issue 2 (10th November 2020) Authors: Chen, Xiaofeng; Wu, Xiaofeng; Wu, Hao; Gu, Yanhong; Shao, Yang; Shao, Qianwen; Zhu, Feipeng; Li, Xiao; Qian, Xiaofeng; Hu, Jun; Zhao, Fengjiao; Mao, Weidong; Sun, Jing; Wang, Jian; Han, Gaohua; Li, Changxian; Xia, Yongxiang; Seesaha, Poshita Kumari; Zhu, Dongqin; Li, Huajun Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. Issue 2 (10th November 2020) Authors: Chen, Xiaofeng; Wu, Xiaofeng; Wu, Hao; Gu, Yanhong; Shao, Yang; Shao, Qianwen; Zhu, Feipeng; Li, Xiao; Qian, Xiaofeng; Hu, Jun; Zhao, Fengjiao; Mao, Weidong; Sun, Jing; Wang, Jian; Han, Gaohua; Li, Changxian; Xia, Yongxiang; Seesaha, Poshita Kumari; Zhu, Dongqin; Li, Huajun Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗